FDA OKs First 'Digital Pill' That Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA approves first pill with sensor to track ingestion
The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an add-on treatment for depression in adults. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first pill with sensor to track ingestion appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Patient Monitoring Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

' Digital Pill', Abilify Mycite, Tells Doctor When Patient Takes It
TUESDAY, Nov. 14, 2017 -- The first drug designed to alert a doctor when a patient takes the medication has been approved by the U.S. Food and Drug Administration. Abilify MyCite (aripiprazole with sensor) has an embedded sensor that sends a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA OKs First'Digital Pill', Abilify Mycite, That Lets Doctors Know It's Been Taken
TUESDAY, Nov. 14, 2017 -- Offering both the promise of better patient compliance with health care, but also fears of a medical " Big Brother, " a newly approved " digital pill " allows physicians to track whether or not it ' s been ingested by... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA approves first drug in U.S. with digital ingestion tracking
(Reuters) - The U.S. Food and Drug Administration said on Monday that it had approved Otsuka Pharmaceutical Co Ltd's Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 14, 2017 Category: American Health Source Type: news

FDA Approves Pill with Sensor that Digitally Tracks if Patients Have Ingested their Medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: eHealth News EU)
Source: eHealth News EU - November 14, 2017 Category: Information Technology Tags: Featured Development Research and Development Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: World Pharma News)
Source: World Pharma News - November 14, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 -- The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 13, 2017 Category: Drugs & Pharmacology Source Type: news

Aripiprazole May Reduce Cocaine Cravings in People With Schizophrenia Aripiprazole May Reduce Cocaine Cravings in People With Schizophrenia
In people with schizophrenia, the dopamine modulator aripiprazole appears to reduce cocaine cravings better than the dopamine blocker perphenazine after an acclimation period, according to a small, double-blind randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Otsuka taps Medibio's quantitative mental health assessment for Abilify
Otsuka, the Japanese pharma company that makes the antipsychotic drug Abilify, has partnered with Australian digital health company Medibio to use Medibio ’s system to assess the efficacy of its flagship product. Medibio uses wearable-derived data about heart rate, motion, and sleep to create objective biomarkers for mental illness. (Source: mobihealthnews)
Source: mobihealthnews - October 10, 2017 Category: Information Technology Source Type: news

Abilify vs. Invega
Title: Abilify vs. InvegaCategory: MedicationsCreated: 9/29/2017 12:00:00 AMLast Editorial Review: 9/29/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 29, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, includ...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, includ...
Source: JEMS: Journal of Emergency Medical Services News - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, includ...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news